Vytrus Biotech S.A. (VYT) - Total Liabilities

Latest as of December 2024: €3.84 Million EUR ≈ $4.49 Million USD

Based on the latest financial reports, Vytrus Biotech S.A. (VYT) has total liabilities worth €3.84 Million EUR (≈ $4.49 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Vytrus Biotech S.A. to assess how effectively this company generates cash.

Vytrus Biotech S.A. - Total Liabilities Trend (2020–2024)

This chart illustrates how Vytrus Biotech S.A.'s total liabilities have evolved over time, based on quarterly financial data. Check Vytrus Biotech S.A. liquidity resilience to evaluate the company's liquid asset resilience ratio.

Vytrus Biotech S.A. Competitors by Total Liabilities

The table below lists competitors of Vytrus Biotech S.A. ranked by their total liabilities.

Company Country Total Liabilities
Carnaby Resources Ltd
AU:CNB
Australia AU$10.04 Million
Solesence, Inc. Common Stock
NASDAQ:SLSN
USA $36.76 Million
Apex Biotechnology Corp
TW:1733
Taiwan NT$494.69 Million
Tambun Indah Land Bhd
KLSE:5191
Malaysia RM100.84 Million
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
Korea ₩93.02 Billion
Handok
KO:002390
Korea ₩536.54 Billion
Aniplus Inc
KQ:310200
Korea ₩147.34 Billion
Canadian Life Companies Split Corp
TO:LFE
Canada CA$168.74 Million

Liability Composition Analysis (2020–2024)

This chart breaks down Vytrus Biotech S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vytrus Biotech S.A. stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.53 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.34 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vytrus Biotech S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vytrus Biotech S.A. (2020–2024)

The table below shows the annual total liabilities of Vytrus Biotech S.A. from 2020 to 2024.

Year Total Liabilities Change
2024-12-31 €3.84 Million
≈ $4.49 Million
-4.57%
2023-12-31 €4.02 Million
≈ $4.70 Million
+23.76%
2022-12-31 €3.25 Million
≈ $3.80 Million
+10.85%
2021-12-31 €2.93 Million
≈ $3.43 Million
+12.83%
2020-12-31 €2.60 Million
≈ $3.04 Million
--

About Vytrus Biotech S.A.

MC:VYT Spain Biotechnology
Market Cap
$159.95 Million
€136.82 Million EUR
Market Cap Rank
#19662 Global
#133 in Spain
Share Price
€19.60
Change (1 day)
+0.51%
52-Week Range
€3.04 - €19.80
All Time High
€19.80
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Ca… Read more